These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38993048)

  • 21. Spatiotemporal patterns of brain iron-oxygen metabolism in patients with Parkinson's disease.
    Yan S; Lu J; Li Y; Cho J; Zhang S; Zhu W; Wang Y
    Eur Radiol; 2024 May; 34(5):3074-3083. PubMed ID: 37853173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of T2*-weighted and QSM contrasts in Parkinson's disease to visualize the STN with MRI.
    Alkemade A; de Hollander G; Keuken MC; Schäfer A; Ott DVM; Schwarz J; Weise D; Kotz SA; Forstmann BU
    PLoS One; 2017; 12(4):e0176130. PubMed ID: 28423027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of quantitative susceptibility mapping methods for iron-sensitive susceptibility imaging at 7T: An evaluation in healthy subjects and patients with Huntington's disease.
    Yao J; Morrison MA; Jakary A; Avadiappan S; Chen Y; Luitjens J; Glueck J; Driscoll T; Geschwind MD; Nelson AB; Villanueva-Meyer JE; Hess CP; Lupo JM
    Neuroimage; 2023 Jan; 265():119788. PubMed ID: 36476567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imaging of nigrosome 1 in substantia nigra at 3T using multiecho susceptibility map-weighted imaging (SMWI).
    Nam Y; Gho SM; Kim DH; Kim EY; Lee J
    J Magn Reson Imaging; 2017 Aug; 46(2):528-536. PubMed ID: 27859983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simulated and experimental phantom data for multi-center quality assurance of quantitative susceptibility maps at 3 T, 7 T and 9.4 T.
    Gustavo Cuña E; Schulz H; Tuzzi E; Biagi L; Bosco P; García-Fontes M; Mattos J; Tosetti M; Engelmann J; Scheffler K; Hagberg GE
    Phys Med; 2023 Jun; 110():102590. PubMed ID: 37116389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Visualizing the deep cerebellar nuclei using quantitative susceptibility mapping: An application in healthy controls, Parkinson's disease patients and essential tremor patients.
    Zhang Y; Huang P; Wang X; Xu Q; Liu Y; Jin Z; Li Y; Cheng Z; Tang R; Chen S; He N; Yan F; Haacke EM
    Hum Brain Mapp; 2023 Mar; 44(4):1810-1824. PubMed ID: 36502376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regionally progressive accumulation of iron in Parkinson's disease as measured by quantitative susceptibility mapping.
    Guan X; Xuan M; Gu Q; Huang P; Liu C; Wang N; Xu X; Luo W; Zhang M
    NMR Biomed; 2017 Apr; 30(4):. PubMed ID: 26853890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative Susceptibility Mapping in Parkinson's Disease.
    Langkammer C; Pirpamer L; Seiler S; Deistung A; Schweser F; Franthal S; Homayoon N; Katschnig-Winter P; Koegl-Wallner M; Pendl T; Stoegerer EM; Wenzel K; Fazekas F; Ropele S; Reichenbach JR; Schmidt R; Schwingenschuh P
    PLoS One; 2016; 11(9):e0162460. PubMed ID: 27598250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2.
    Barbosa JH; Santos AC; Tumas V; Liu M; Zheng W; Haacke EM; Salmon CE
    Magn Reson Imaging; 2015 Jun; 33(5):559-65. PubMed ID: 25721997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative susceptibility mapping as an indicator of subcortical and limbic iron abnormality in Parkinson's disease with dementia.
    Li DTH; Hui ES; Chan Q; Yao N; Chua SE; McAlonan GM; Pang SYY; Ho SL; Mak HKF
    Neuroimage Clin; 2018; 20():365-373. PubMed ID: 30128274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous quantitative susceptibility mapping (QSM) and R2* for high iron concentration quantification with 3D ultrashort echo time sequences: An echo dependence study.
    Lu X; Ma Y; Chang EY; He Q; Searleman A; von Drygalski A; Du J
    Magn Reson Med; 2018 Apr; 79(4):2315-2322. PubMed ID: 29314215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 3D texture analyses within the substantia nigra of Parkinson's disease patients on quantitative susceptibility maps and R2
    Li G; Zhai G; Zhao X; An H; Spincemaille P; Gillen KM; Ku Y; Wang Y; Huang D; Li J
    Neuroimage; 2019 Mar; 188():465-472. PubMed ID: 30578927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deep gray matter iron measurement in patients with liver cirrhosis using quantitative susceptibility mapping: Relationship with pallidal T
    Lee S; Nam Y; Jang J; Na GH; Kim DG; Shin NY; Choi HS; Jung SL; Ahn KJ; Kim BS
    J Magn Reson Imaging; 2018 May; 47(5):1342-1349. PubMed ID: 28815906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methods for the computation of templates from quantitative magnetic susceptibility maps (QSM): Toward improved atlas- and voxel-based analyses (VBA).
    Hanspach J; Dwyer MG; Bergsland NP; Feng X; Hagemeier J; Bertolino N; Polak P; Reichenbach JR; Zivadinov R; Schweser F
    J Magn Reson Imaging; 2017 Nov; 46(5):1474-1484. PubMed ID: 28263417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative susceptibility mapping (QSM) minimizes interference from cellular pathology in R2* estimation of liver iron concentration.
    Li J; Lin H; Liu T; Zhang Z; Prince MR; Gillen K; Yan X; Song Q; Hua T; Zhao X; Zhang M; Zhao Y; Li G; Tang G; Yang G; Brittenham GM; Wang Y
    J Magn Reson Imaging; 2018 Oct; 48(4):1069-1079. PubMed ID: 29566449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-dimensional high-resolution simultaneous quantitative mapping of the whole brain with 3D-QALAS: An accuracy and repeatability study.
    Fujita S; Hagiwara A; Hori M; Warntjes M; Kamagata K; Fukunaga I; Andica C; Maekawa T; Irie R; Takemura MY; Kumamaru KK; Wada A; Suzuki M; Ozaki Y; Abe O; Aoki S
    Magn Reson Imaging; 2019 Nov; 63():235-243. PubMed ID: 31445118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multi-centre, multi-vendor reproducibility of 7T QSM and R
    Rua C; Clarke WT; Driver ID; Mougin O; Morgan AT; Clare S; Francis S; Muir KW; Wise RG; Carpenter TA; Williams GB; Rowe JB; Bowtell R; Rodgers CT
    Neuroimage; 2020 Dec; 223():117358. PubMed ID: 32916289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Feasibility of ultrashort echo time quantitative susceptibility mapping with a 3D cones trajectory in the human brain.
    Jang H; Sedaghat S; Athertya JS; Moazamian D; Carl M; Ma Y; Lu X; Ji A; Chang EY; Du J
    Front Neurosci; 2022; 16():1033801. PubMed ID: 36419458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of MRI contrast agent concentration by quantitative susceptibility mapping (QSM): application to estimation of cerebral blood volume during steady state.
    Lind E; Knutsson L; Kämpe R; Ståhlberg F; Wirestam R
    MAGMA; 2017 Dec; 30(6):555-566. PubMed ID: 28631203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigating the effect of oblique image acquisition on the accuracy of QSM and a robust tilt correction method.
    Kiersnowski OC; Karsa A; Wastling SJ; Thornton JS; Shmueli K
    Magn Reson Med; 2023 May; 89(5):1791-1808. PubMed ID: 36480002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.